Compare Eli Lilly And Co (LLY) vs MobilEye Global Inc (MBLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs MobilEye Global Inc — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while MobilEye Global Inc trades at $7.1 (market cap $6.00B). The key difference: Eli Lilly And Co is far larger — about 173.3× MobilEye Global Inc's market cap, and Eli Lilly And Co pays a 0.59% dividend while MobilEye Global Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and MobilEye Global Inc for 15 Days on average.
| LLY | MBLY | |
|---|---|---|
Market Cap | $1.04T | $6.00B |
Volume | 3,064,878 | 7,007,849 |
Sector | Health | Consumer Cyclical |
52-Week High | $1.28K | $15.42 |
52-Week Low | $799.57 | $6.56 |
Typical Hold Time | 93 Days | 15 Days |
Enterprise Value | $1.09T | $4.56B |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company demonstrates exceptional profitability with 83.4% gross margins and 33.53% net income margins, supported by dominant positioning in weight-loss and diabetes treatments. Recent clinical trial successes for next-generation drugs and expanded FDA approvals reinforce growth prospects.
LLY presents compelling growth potential with analyst consensus target of $1,350 representing 15% upside, though elevated valuations (P/E 39.26) and increasing competition in obesity drugs pose risks. Strong institutional support (73% buy ratings) and positive pipeline developments support continued momentum, but investors should monitor execution risks and market saturation concerns.
Mobileye Global (MBLY) trades at $7.06, down 1.26% with bearish technical signals despite recent earnings beats. The company shows strong revenue growth to $1.9B in 2025 but faces significant profitability challenges with a -201.49% net income margin. Analyst consensus leans bullish with a $10.83 price target, while institutional activity shows mixed positioning amid autonomous driving sector volatility.
MBLY presents a high-risk opportunity with substantial upside potential if profitability improves, but current negative margins and bearish technicals suggest caution. The autonomous driving market position remains strong, though execution risks and competitive pressures could limit near-term gains despite Wall Street's optimistic price targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About MobilEye Global Inc
Mobileye Global Inc. is a global leader in the development and deployment of Advanced Driver Assistance Systems (ADAS) and autonomous driving technologies. The company specializes in computer vision, machine learning, and data analysis to create sensing, mapping, and driving policy solutions. Mobileye's technology, including its EyeQ system-on-chips and its crowd-sourced mapping platform (REM), is integrated into vehicles worldwide, aiming to improve road safety and enable the future of autonomous mobility.
Read more on MBLY →
